Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00100711 · ClinicalTrials.gov registry record · Phase 2
Study of Motexafin Gadolinium (MGd) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Phase 2 study, sponsored by Pharmacyclics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT00100711 is a Phase 2 study that was terminated before completion, run by Pharmacyclics. The registered enrollment target is 27 participants.
The verdict
NCT00100711, a Phase 2 study, was terminated before completion, sponsored by Pharmacyclics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
The primary purpose of this study is to determine if motexafin gadolinium may be an effective treatment for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Secondly, the duration of response and the time during which patients survive without chronic lymphocytic leukemia or small lymphocytic lymphoma worsening will be evaluated. Additionally, the patient's response to motexafin gadolinium will be compared to the response of the patient's cells in a laboratory to motexafin gadolinium.
Interventions
- DRUG Motexafin Gadolinium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2004-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00100711
The ClinicalTrials.gov registry entry for NCT00100711 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pharmacyclics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Motexafin Gadolinium is the first listed.
NCT00100711 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00100711 about?
NCT00100711 is a clinical study titled "Study of Motexafin Gadolinium (MGd) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma". The primary purpose of this study is to determine if motexafin gadolinium may be an effective treatment for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Secondly, the duration of response and the time during which patients survive without chronic lymphocytic ...
What is the current status of trial NCT00100711?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2004-10.
What interventions are being tested in trial NCT00100711?
The interventions under investigation include: Motexafin Gadolinium (DRUG).
Who is sponsoring clinical trial NCT00100711?
This trial is sponsored by Pharmacyclics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.